WVE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now (speculative). The stock is sitting near support with bearish momentum fading, options positioning is notably bullish (puts relatively light), and Wall Street sentiment/targets have sharply moved up on WVE-007 obesity/body-composition data. For an impatient buyer, the risk/reward favors entry near ~$13 with a clear nearby technical line in the sand around ~$12.7 support.
Price is $13.14 (below the pivot $13.486), with key support at S1 ~$12.738 and resistance at R1 ~$14.235. MACD histogram (-0.257) remains below zero but is negatively contracting, which often signals downside momentum is weakening and a base may be forming. RSI(6) ~30.8 is near oversold territory, supporting a rebound/setup from support. Moving averages are converging, consistent with consolidation after a move; the next directional break likely matters. A clean push back above the pivot ($13.49) improves odds of a move toward ~$14.24; losing ~$12.74 increases downside risk toward ~$12.28.
Strong obesity/body recomposition narrative tailwind (market expansion and improved access/coverage mentioned in news); expanding obesity market increases strategic value of differentiated mechanisms.
Company-specific catalyst framework echoed by analysts: WVE-007 data trajectory (higher doses/longer follow-up expected to improve), plus additional pipeline catalysts cited by Street (e.g., WVE-006 updates; WVE-N531 NDA timing per analyst commentary).
Multiple recent price-target raises and ‘best ideas’ inclusion can support continued inflows/attention.
Fundamentals remain loss-heavy and revenue is volatile (biotech profile), which can cap upside between data releases.
Competitive obesity landscape (Novo/Lilly and others) raises the bar; if Wave’s efficacy at higher doses doesn’t catch up while maintaining its body-composition/safety edge, sentiment could reverse.
Very high implied volatility means the stock can reprice sharply on any incremental data or timelines slipping.
Latest reported quarter: 2025/Q3. Revenue fell to ~$7.61M (reported -199.11% YoY), while net income was -$53.85M (reported -12.83% YoY) and EPS was -$0.32 (reported -31.91% YoY). This reflects a company still firmly in investment/loss mode; the bull case is primarily pipeline/value-of-data rather than current operating performance.
Analyst trend is decisively improving: a cluster of Buy/Outperform/Overweight reiterations plus large target increases in mid-to-late December 2025 (e.g., Citi $30 from $16, Cantor $34 from $12, B. Riley $37 from $19, Wedbush $33 from $20 and Best Ideas, Oppenheimer $32 from $24, Truist $50 from $36, H.C. Wainwright $30 from $22). Wall Street ‘pro’ view: WVE-007 has a differentiated ‘quality weight loss/body recomposition’ angle (visceral fat loss + lean mass preservation, tolerability) with potential to complement GLP-1s. ‘Con’ view: proof is still early and dose-dependent; commercial positioning depends on stronger efficacy at higher doses and clean longer-term safety.
